Analyst Price Target is $145.92
▼ -3.29% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $145.92, with a high forecast of $185.00 and a low forecast of $100.00. The average price target represents a -3.29% upside from the last price of $150.88.
Current Consensus is
Moderate Buy
The current consensus among 13 investment analysts is to moderate buy stock in Glaukos. This Moderate Buy consensus rating has held steady for over two years.
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Read More
